20 On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the "401K Plan") pursuant to which, all employees meeting eligibility requirements are able to participate. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Management's Discussion In neurodegenerative disease, the Company's drug candidate NE3107 inhibits activation of inflammatory actions extracellular singleregulated kinase ...

Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8%, primarily due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales [4]. - A new distribution center was opened in South America to support regional growth [1]. - Strategic partnerships were formed with local retailers in Southeast Asia to enhance market penetration [2]. Product Development - Launched three new products in the tech segment, which accounted for 25% of total revenue [3]. - R&D investment increased by 10% to accelerate innovation and product differentiation [4]. - Customer feedback on the latest product line has been overwhelmingly positive, with a 95% satisfaction rate [1]. Operational Efficiency - Implemented a new supply chain management system, reducing delivery times by 15% [2]. - Automation initiatives in manufacturing led to a 10% reduction in production costs [3]. - Employee training programs were expanded, resulting in a 20% improvement in operational productivity [4]. Sustainability Initiatives - Achieved a 30% reduction in carbon emissions through the adoption of renewable energy sources [1]. - Introduced eco-friendly packaging for all product lines, reducing plastic usage by 25% [2]. - Partnered with environmental organizations to promote sustainable practices across the supply chain [3]. Corporate Governance - Appointed two new independent directors to the board, enhancing governance and oversight [4]. - Conducted a comprehensive review of corporate policies to ensure compliance with global standards [1]. - Increased transparency in financial reporting, earning recognition from industry watchdogs [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State or other jurisdictio ...

Previously, the Company was obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of shares of the Company's common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by the Company from NeurMedix, and subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affil ...

On August 20, 2021, the Company awarded 58,759 restricted stock units ("RSUs") to the Company's President and CEO under the Company's 2019 Omnibus Incentive Equity Plan (the "2019 Omnibus Plan") as his salary for the period from April 27, 2021, the date of his appointment, through December 31, 2021. The number of RSUs awarded was based on a prorated annual base salary of $600,000 at a 10% discount to the grant date fair value of $7.74 per share of the Company's common stock. Each RSU awarded to the CEO enti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State o ...

Part I [Business](index=5&type=section&id=Item%201.%20Business) BioVie Inc. is a clinical-stage company developing drug therapies for chronic debilitating conditions, focusing on liver and neurodegenerative diseases, protected by patents and subject to extensive regulation [Company Overview and Pipeline](index=5&type=section&id=Company%20Overview%20and%20Pipeline) BioVie is a clinical-stage company developing therapies for chronic conditions, focusing on liver disease and neurodegenerative diseases[10](index=10&type=chunk) - The company's liver disease candidate, BIV201 (terlipressin), targets refractory ascites and is in a Phase 2b trial with top-line results expected in mid-2023[11](index=11&type=chunk) - The neurodegenerative disease candidate, NE3107, acquired from NeurMedix, is being evaluated for Alzheimer's Disease (Phase 3 trial) and Parkinson's Disease (Phase 2 trial)[13](index=13&type=chunk)[14](index=14&type=chunk) [Liver Cirrhosis Program (BIV201)](index=6&type=section&id=Liver%20Cirrhosis%20Program%20(BIV201)) BIV201 is an orphan drug candidate for treating ascites due to chronic liver cirrhosis, with a Phase 2b study initiated in June 2021 and a potential pivotal Phase 3 trial planned for 2023[18](index=18&type=chunk)[21](index=21&type=chunk) - The company has developed a proprietary novel liquid formulation of terlipressin with confirmed room temperature stability for 18 months, a key differentiator from other terlipressin products requiring refrigeration[22](index=22&type=chunk) - BIV201 has received FDA Fast-Track status and Orphan Drug designation for ascites and hepatorenal syndrome (HRS), with the total addressable market for ascites estimated to exceed **$650 million**[23](index=23&type=chunk) [Neurodegenerative Disease Program (NE3107)](index=9&type=section&id=Neurodegenerative%20Disease%20Program%20(NE3107)) NE3107 is a novel, orally administered small molecule designed to inhibit inflammation-driven insulin resistance, believed to play a fundamental role in Alzheimer's and Parkinson's Disease[33](index=33&type=chunk) - A potentially pivotal Phase 3 study for NE3107 in mild to moderate Alzheimer's disease was initiated on August 5, 2021, with primary completion targeted for mid-2023[33](index=33&type=chunk) - A Phase 2 study (NM201) for NE3107 in Parkinson's disease patients was initiated on January 20, 2022, to assess safety, tolerability, and pro-motoric impact, with topline results expected by the end of calendar year 2022[44](index=44&type=chunk) [Intellectual Property](index=11&type=section&id=Intellectual%20Property) BIV201 has Orphan Drug Designations in the U.S. for hepatorenal syndrome and ascites, and the company has filed a PCT application for its novel liquid formulation of terlipressin[50](index=50&type=chunk) NE3107 U.S. Patent Portfolio Summary (as of Aug 22, 2022) | Category | Count | | :--- | :--- | | Issued U.S. Patents | 15 | | Pending U.S. Patent Application | 1 | | Pending U.S. PCT Application | 1 | | Issued Foreign Patents | 6 | [Government Regulation](index=12&type=section&id=Government%20Regulation) The company's products are subject to extensive regulation by the FDA in the U.S. and comparable foreign authorities, covering research, development, testing, manufacturing, and marketing[55](index=55&type=chunk) - The U.S. drug development process involves preclinical testing, an Investigational New Drug (IND) application, and three phases of human clinical trials (Phase 1, 2, and 3) to establish safety and efficacy before submitting a New Drug Application (NDA) or Biologics License Application (BLA)[58](index=58&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk)[63](index=63&type=chunk) - The company may utilize programs like Orphan Drug Designation, which provides seven years of market exclusivity for a rare disease, and Fast Track designation to expedite the review process for drugs addressing unmet medical needs[75](index=75&type=chunk)[76](index=76&type=chunk)[78](index=78&type=chunk) [Risk Factors](index=17&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks, including no revenue, substantial losses, dependence on clinical trial success, and the need for significant additional capital to fund operations - **Business & Financial Risks:** The company has no approved products, has never generated revenue, and will require substantial additional capital to fund operations; failure to raise funds could force a cessation of operations[86](index=86&type=chunk)[87](index=87&type=chunk)[106](index=106&type=chunk) - **Clinical & Regulatory Risks:** Drug development is a lengthy and uncertain process, product candidates may be found unsafe or ineffective in clinical trials, and failure to obtain FDA approval would prevent commercialization; the COVID-19 pandemic could also disrupt clinical trials and supply chains[113](index=113&type=chunk)[117](index=117&type=chunk)[119](index=119&type=chunk) - **Competitive & Market Risks:** The company faces competition from established pharmaceutical companies, and even if approved, its products may not be adopted over existing treatments; failure to protect intellectual property could compromise its competitive advantage[155](index=155&type=chunk)[158](index=158&type=chunk)[143](index=143&type=chunk) - **Stock & Ownership Risks:** Investors face potential dilution from future equity offerings and milestone-based share issuances, while executive officers and directors beneficially own approximately **81.8%** of outstanding common stock, giving them significant control over management and company affairs as of September 13, 2022[167](index=167&type=chunk)[170](index=170&type=chunk)[172](index=172&type=chunk) [Unresolved Staff Comments](index=32&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments from the SEC - There are no unresolved staff comments[191](index=191&type=chunk) [Properties](index=32&type=section&id=Item%202.%20Properties) The company leases office space for its headquarters in Carson City, Nevada, and maintains an office in San Diego, California - The company's headquarters is located at 680 W. Nye Lane, Carson City, Nevada, under a 12-month lease that began November 1, 2021, with an annual rent of **$2,200**[192](index=192&type=chunk) - The company leases an office at 5090 Shoreham Place, San Diego, California, under a 38-month lease that commenced on March 1, 2022, with monthly base rent of **$4,175** starting June 1, 2022[193](index=193&type=chunk) [Legal Proceedings](index=32&type=section&id=Item%203.%20Legal%20Proceedings) The company reports that it is not a party to any material legal proceedings - The company is not a party to any material legal proceedings[194](index=194&type=chunk) [Mine Safety Disclosures](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company's operations - Not applicable[195](index=195&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=33&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) During the fiscal year ended June 30, 2022, the company did not engage in any issuer repurchases of its common stock - There were no issuer repurchases of common stock during the year ended June 30, 2022[197](index=197&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=33&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) For FY 2022, the company's net loss decreased to **$26.1 million** from **$130.2 million** due to a one-time IPR&D expense in 2021, while operating expenses increased from clinical trials and expanded operations, leading to substantial doubt about its going concern ability [Results of Operations](index=34&type=section&id=Results%20of%20Operations) Comparison of Operations (Year Ended June 30) | Metric | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | **Net Loss** | $26.1M | $130.2M | -$104.1M | | **Total Operating Expenses** | $27.3M | $138.1M | -$110.8M | | Research & Development | $17.3M | $2.5M | +$14.8M | | Selling, General & Admin | $9.8M | $4.6M | +$5.2M | - The decrease in net loss was primarily due to a one-time **$130.6 million** In-Process Research and Development (IPR&D) expense recorded in June 2021 related to the NeurMedix asset acquisition[205](index=205&type=chunk)[206](index=206&type=chunk) - R&D expenses increased by **$14.8 million**, driven by clinical operations for the Alzheimer's Phase 3 trial, initiation of the Parkinson's Phase 2 trial, and an expanded clinical team[207](index=207&type=chunk) - SG&A expenses increased by **$5.2 million** due to higher employee compensation (including **$2.4 million** in stock-based compensation), legal fees, and investor relations costs associated with expanded operations[209](index=209&type=chunk) [Capital Resources and Liquidity](index=35&type=section&id=Capital%20Resources%20and%20Liquidity) Financial Position as of June 30, 2022 | Metric | Amount | | :--- | :--- | | Working Capital | $14.6 million | | Cash | $18.6 million | | Stockholders' Equity | $3.7 million | | Accumulated Deficit | $251 million | - The company's ability to continue as a going concern is in substantial doubt, as its future viability depends on raising additional capital to finance operations[217](index=217&type=chunk)[221](index=221&type=chunk) - Subsequent to the fiscal year-end, the company raised capital through a Controlled Equity Offering Sales Agreement (net proceeds of **$5.9 million** as of Sep 12, 2022) and a private placement with Acuitas (gross proceeds of **$6 million**)[212](index=212&type=chunk)[213](index=213&type=chunk)[214](index=214&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures and internal control over financial reporting were effective as of June 30, 2022 - Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2022[230](index=230&type=chunk) - Management concluded that the company's internal control over financial reporting was effective as of June 30, 2022[231](index=231&type=chunk) Part III [Directors, Executive Officers and Corporate Governance](index=39&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) The company's leadership includes CEO Cuong Do and Chairman Terren Peizer, with an eight-member board, six independent directors, and three standing committees, all operating under a code of ethics - The executive team is led by Cuong Do (CEO & President), Terren Peizer (Chairman), Joanne Wendy Kim (CFO), and Joseph M. Palumbo, MD (Chief Medical Officer)[235](index=235&type=chunk) - The Board of Directors has determined that six of its eight members are independent: Messrs. Lang, Sherman, Berman, Gorlin, Hariri, and Rogich[270](index=270&type=chunk) - The Board has three standing committees: Audit, Compensation, and Nominating and Corporate Governance, each composed solely of independent directors[272](index=272&type=chunk) Board Diversity Matrix (As of September 13, 2022) | Category | Count | | :--- | :--- | | **Total Directors** | **8** | | **Gender Identity** | | | Male | 8 | | Female | 0 | | **Demographic Background** | | | Asian | 1 | | White | 4 | | Did Not Disclose | 3 | [Executive Compensation](index=47&type=section&id=Item%2011.%20Executive%20Compensation) For fiscal year 2022, CEO Cuong Do's total compensation was **$4.54 million**, largely from stock and option awards, while non-employee directors received stock options, all under the 2019 Omnibus Equity Incentive Plan FY 2022 Named Executive Officer Compensation | Name and Position | Salary | Bonus | Stock/Option Awards | Total Compensation | | :--- | :--- | :--- | :--- | :--- | | **Cuong Do** (CEO & President) | $300,000 | $400,000 | $3,842,821 | $4,542,821 | | **Joanne Wendy Kim** (CFO) | $235,000 | $127,656 | $582,343 | $944,999 | | **Joseph Palumbo** (CMO) | $333,333 | $239,167 | $244,465 | $816,965 | - Non-employee directors received compensation in the form of option awards, with grant date fair values ranging from approximately **$399,000** to **$425,000** for fiscal year 2022[299](index=299&type=chunk) - As of June 30, 2022, there were **3,705,157 shares** available for new awards under the 2019 Omnibus Equity Incentive Plan[305](index=305&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=53&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) As of September 13, 2022, the company's ownership is highly concentrated, with Chairman Terren Peizer holding approximately **81.3%** and all directors and executive officers as a group owning approximately **82.5%** of outstanding common stock Beneficial Ownership (as of September 13, 2022) | Beneficial Owner | Percentage Ownership | | :--- | :--- | | Terren Peizer (Chairman) | 81.3% | | All directors and executive officers as a group | 82.5% | - The percentage ownership is based on **30,165,319 shares** of common stock outstanding as of September 13, 2022[309](index=309&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=55&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) The company engaged in a significant related party private placement with Acuitas, an entity controlled by Chairman Terren Peizer, for **$6 million** in stock and warrants, with all such transactions subject to audit committee or Board approval - On July 15, 2022, the company entered into a securities purchase agreement with Acuitas (an entity controlled by Chairman Terren Peizer) for a private placement of **3,636,364 shares** and warrants to purchase **7,272,728 shares** for an aggregate price of **$6 million**, which closed on August 15, 2022[318](index=318&type=chunk) - The company has a formal procedure for the review and approval of related party transactions by either the audit committee or the Board of Directors[319](index=319&type=chunk) [Principal Accountant Fees and Services](index=55&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) EisnerAmper LLP, the company's principal accountant, billed **$223,102** for audit services in FY 2022, an increase from the prior year, with all services pre-approved by the Audit Committee Auditor Fees | Fee Category | 2022 | 2021 | | :--- | :--- | :--- | | Audit Fees | $223,102 | $191,970 | | **Total** | **$223,102** | **$191,970** | - The Audit Committee is responsible for appointing, setting compensation, and overseeing the work of the independent registered public accounting firm, and has a policy to pre-approve all services[323](index=323&type=chunk) Part IV [Exhibits and Financial Statement Schedules](index=57&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists all exhibits filed with the Form 10-K report, including corporate governance documents, material agreements, and certifications - This section lists all exhibits filed with the annual report, including corporate governance documents, material agreements, and certifications[330](index=330&type=chunk)[331](index=331&type=chunk)[332](index=332&type=chunk) Financial Statements [Report of Independent Registered Public Accounting Firm](index=62&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) EisnerAmper LLP issued an unqualified opinion on the financial statements but included a "Going Concern" paragraph due to recurring losses and negative cash flows, identifying the valuation of notes payable and derivative liabilities as a critical audit matter - The auditor expressed an unqualified opinion that the financial statements are presented fairly in all material respects[338](index=338&type=chunk) - A 'Going Concern' paragraph was included, citing recurring losses and negative cash flows from operations, which raise substantial doubt about the company's ability to continue as a going concern[339](index=339&type=chunk) - The valuation and accounting for notes payable and related derivative liabilities were identified as a critical audit matter due to complexity and subjective judgment[346](index=346&type=chunk) [Financial Statements Data](index=64&type=section&id=Financial%20Statements%20Data) The company's financial statements show a significant increase in cash to **$18.6 million** and total liabilities to **$16.4 million** as of June 30, 2022, while the net loss for FY 2022 significantly reduced to **$26.1 million** from **$130.2 million** in FY 2021, primarily due to a one-time IPR&D expense Balance Sheet Highlights (as of June 30) | Account | 2022 | 2021 | | :--- | :--- | :--- | | Cash | $18,641,716 | $4,511,642 | | Total Assets | $20,114,594 | $6,046,689 | | Total Liabilities | $16,443,659 | $996,374 | | Total Stockholders' Equity | $3,670,935 | $5,050,315 | | Accumulated Deficit | ($250,969,890) | ($224,885,422) | Statement of Operations Highlights (Year Ended June 30) | Account | 2022 | 2021 | | :--- | :--- | :--- | | Research and development expenses | $17,258,341 | $2,544,648 | | In process R&D expenses | $0 | $130,642,858 | | Selling, general and administrative | $9,765,259 | $4,637,256 | | **Net Loss** | **($26,084,468)** | **($130,249,204)** | | Net Loss Per Share (Basic & Diluted) | ($1.06) | ($14.82) | Cash Flow Highlights (Year Ended June 30) | Account | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($18,990,850) | ($10,453,047) | | Net cash provided by financing activities | $33,120,924 | $14,927,494 | | **Net increase in cash** | **$14,130,074** | **$4,474,447** | [Notes to Financial Statements](index=68&type=section&id=Notes%20to%20Financial%20Statements) The notes provide critical details on accounting policies, related party transactions, debt, and equity, including the 'going concern' uncertainty, the NeurMedix asset acquisition, a **$15 million** loan with warrants and conversion options, and significant stock option grants [Note 2. Liquidity and Going Concern](index=69&type=section&id=Note%202.%20Liquidity%20and%20Going%20Concern) The financial statements were prepared assuming the company will continue as a going concern, but recurring losses and negative cash flows raise substantial doubt about this ability[363](index=363&type=chunk) - The company's future viability is largely dependent on its ability to raise additional capital to finance operations[364](index=364&type=chunk) [Note 5. Related Party Transactions](index=74&type=section&id=Note%205.%20Related%20Party%20Transactions) In June 2021, the company acquired assets from NeurMedix, a related party affiliate, in exchange for **8,361,308 shares** of common stock and approximately **$2.3 million** in cash, with the total consideration expensed as in-process R&D[387](index=387&type=chunk)[388](index=388&type=chunk) - The NeurMedix APA includes contingent consideration of up to **18 million shares** of common stock, issuable upon the achievement of four specific clinical, regulatory, and commercial milestones[388](index=388&type=chunk) [Note 7. Notes Payable](index=79&type=section&id=Note%207.%20Notes%20Payable) On November 30, 2021, the company entered into a loan agreement for up to **$20 million**, drawing an initial **$15 million**, bearing interest at the greater of **10.75%** or prime + **7.00%**[410](index=410&type=chunk) - The loan includes a conversion option for the lender to convert up to **$5.0 million** of principal into common stock at **$6.98 per share**[412](index=412&type=chunk) - In connection with the loan, the company issued warrants to purchase **361,002 shares** of common stock at an exercise price of **$5.82 per share**[413](index=413&type=chunk) [Note 9. Equity Transactions](index=83&type=section&id=Note%209.%20Equity%20Transactions) In August 2021, the company closed a public offering, issuing **2.5 million shares** at **$8.00 per share**, resulting in net proceeds of approximately **$17.8 million**[433](index=433&type=chunk) - During fiscal year 2022, the company granted **2,724,689 stock options**, primarily to the executive management team and independent directors[426](index=426&type=chunk) - Stock-based compensation expense was approximately **$5.8 million** for the year ended June 30, 2022, compared to **$3.0 million** in the prior year[429](index=429&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State or ot ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State o ...